Securities Code: 002365 Securities Abbreviation: Yong'an Pharmaceutical Announcement No.: 2026-19 Qianjiang Yong'an Pharmaceutical Co., Ltd. Announcement on Accruing Impairment Losses on Receivables and Assets for 2025
The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.
Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the Fourteenth Meeting of the Seventh Board of Directors on April 15, 2026, and deliberated and passed the "Proposal on Accruing Impairment Losses on Receivables and Assets for 2025". This matter does not require submission to the shareholders' meeting for deliberation. The specific details are hereby announced as follows:
I. Overview of Accruing Impairment Losses on Receivables and Assets for 2025
In accordance with the "Accounting Standards for Business Enterprises," the "Listing Rules of the Shenzhen Stock Exchange," and other relevant regulations, to more truthfully, accurately, and objectively reflect the Company's financial position, asset value, and operating results, based on the principle of prudence, the Company and its subsidiaries within the consolidated financial statements scope have conducted a comprehensive inventory and impairment test of various assets. Corresponding impairment losses have been accrued for assets that may incur impairment as of December 31, 2025, within the consolidated financial statements scope.